Designing Next Generation Cardiometabolic Outcome Trials for Obesity Medicines JACC Semaglutide for Weight Loss, Ivermectin for Mild #COVID19, USPSTF Guideline on Screening for Vitamin D Deficiency, and more. Anne Cappola, MD, Associate Editor of JAMA, summarizes the April 13, 2021, issue. Viking Therapeutics' GLP 1 pill candidate shows promise in latest study MM+M Medical Marketing and Media Semaglutide, Tirzepatide, Retatrutide and Cagrilintide are often lumped together, but they are not doing the same thing. : r Wegovy The Rise of Next Generation Incretins: A New Era in Metabolic Medicine ESSI Novo Nordisk's Ozempic successor disappointed Wall Street again